New HPV vaccine enters first human tests
NCT ID NCT05208710
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new vaccine called PANHPVAX in 45 healthy adults aged 18-45. The vaccine targets a part of the HPV virus (L2 antigen) to potentially protect against multiple HPV types. The main goal is to check safety and how well the body's immune system responds to different doses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Department of Clinical Pharmacology and Pharmacoepidemiology
RECRUITINGHeidelberg, 69120, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could Self-Sampling revolutionize cervical cancer screening?
- Texting parents could be key to curbing HPV-Related cancers
- Pocket-sized HIV test could bring same-day diagnosis to community clinics
- Can anal cancer treatment spare sexual well-being? a study tracks the toll over two years.
- Simple blood test could spot returning throat cancer sooner
- Double probe heat therapy may slash cervical cancer risk in HIV-positive women